DoD Pancreatic Cancer Research Program anticipated funding opportunities for FY23

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

The Trump administration has a fight on its hands as it pushes forward with a plan to exert greater political control over government funding of science.

ARPA-H awards up to $160M to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health, an agency within the U.S. Department of Health and Human Services, announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program—a critical investment toward bringing new treatments to patients faster and curing rare genetic pediatric diseases.

July 10, 2026

Vol.52 No.27

In Brief

Cancer Research Institute issues 93 awards totaling $37 million

The Cancer Research Institute announced its largest-ever annual grantmaking—93 awards totaling $37 million—as federal funding for cancer research remains uncertain.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells, UMiami study finds

A “tumor-on-a-chip” model is giving scientists a live look at how pancreatic cancer can recruit the body’s own immune cells to help tumors survive. The study reveals possible new targets to weaken the cancer’s defenses and make treatments work better.

July 10, 2026

Vol.52 No.27

In the Archives

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

When Robert Mayer was only a few years out of residency, in the 1970s, he signed on as an investigator of the NCI-supported Gastrointestinal Tumor Study Group, which conducted research into colorectal, gastric, and pancreatic cancers.

June 26, 2026

Vol.52 No.25

By Sara Willa Ernst

DoD Pancreatic Cancer Research Program anticipated funding opportunities for FY23

YOU MAY BE INTERESTED IN

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

ARPA-H awards up to $160M to advance personalized curative medicines for rare genetic diseases

Cancer Research Institute issues 93 awards totaling $37 million

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

Tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells, UMiami study finds

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

Renew today!

Subscriber content

Never miss an issue!

Login